Insmed Inc (INSM)

Currency in USD
136.33
+1.30(+0.96%)
Closed·
136.330.00(0.00%)
·
Earnings results expected in 6 days
INSM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
134.94137.22
52 wk Range
63.81212.75
Key Statistics
Prev. Close
136.33
Open
136
Day's Range
134.94-137.22
52 wk Range
63.81-212.75
Volume
1.34M
Average Vol. (3m)
2.26M
1-Year Change
87.5417%
Book Value / Share
3.46
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
INSM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
212.70
Upside
+56.02%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Insmed Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

Analyst Ratings

21 Buy
0 Hold
0 Sell
Ratings:
21 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 212.70
(+56.02% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Guggenheim
Buy230.00+68.71%227.00MaintainApr 16, 2026
RBC Capital
Buy216.00+58.44%212.00MaintainApr 14, 2026
Raymond James
Buy200.00+46.70%-New CoverageApr 09, 2026
BofA Securities
Buy212.00+55.51%213.00MaintainApr 08, 2026
Stifel
Buy208.00+52.57%-MaintainApr 08, 2026

Insmed Inc SWOT Analysis


Market Opportunities
Delve into Insmed's strategy in targeting underserved patient populations, potentially driving significant revenue growth and market leadership in rare diseases
Financial Outlook
Analysts project EPS of -5.57 and -4.93 for the next two fiscal years, with price targets ranging from $80 to $109, reflecting strong growth potential
Pipeline Potential
Explore Insmed's promising pipeline, including brensocatib for bronchiectasis, with projected U.S. sales of up to $3.8 billion by 2034
Rare Disease Pionee
Insmed's focus on serious and rare diseases positions it as a significant player in niche markets with high unmet medical needs and potential for premium pricing
Read full SWOT analysis

Insmed Inc Earnings Call Summary for Q4/2025

  • Insmed Q4 2025 reported mixed results with EPS of -$1.54 (missing forecasts by 31.62%) while revenue reached $263.8 million (exceeding expectations by 26.71%), driven by strong BRINSUPRI sales
  • Despite the earnings miss, the stock rose 1.56% to $153.46 in pre-market trading, reflecting investor confidence in the company's revenue growth trajectory
  • BRINSUPRI generated $144.6 million in its first full quarter, establishing Insmed's leadership in the bronchiectasis market with 'no competition on the immediate horizon'
  • Management projects at least $1 billion in BRINSUPRI revenue for 2026, with total company revenue expected to more than double from 2025 levels
  • CEO Will Lewis emphasized the company's path to cash flow positivity without additional capital raising, describing it as an 'inevitability' despite current profitability challenges
Last Updated: 02/19/2026, 09:19 AM
Read Full Transcript
Insmed investor slides for Q4/2025
Insmed Q4 2025 slides
Last Update: Feb 19, 2026
See full investor slides

Earnings

Latest Release
Feb 19, 2026
EPS / Forecast
-1.54 / -1.17
Revenue / Forecast
263.8M / 208.2M
EPS Revisions
Last 90 days

INSM Income Statement

Compare INSM to Peers and Sector

Metrics to compare
INSM
Peers
Sector
Relationship
P/E Ratio
−23.0x−2.6x−0.5x
PEG Ratio
1.51−0.090.00
Price / Book
39.8x1.6x2.6x
Price / LTM Sales
48.5x10.8x3.2x
Upside (Analyst Target)
56.0%303.7%48.8%
Fair Value Upside
Unlock10.2%6.9%Unlock

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
106.57M49.37%14.53B
Other Institutional Investors
123.91M50.63%16.89B
Public Companies & Retail Investors
0.000.00%0.00
Total
230.48M100.00%31.42B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
The Vanguard Group, Inc.9.76%21,076,3442,873,338
Darwin Global Management Limited9.70%20,933,2772,853,834

People Also Watch

1,096.51
SNDK
+3.04%
309.49
ALNY
+2.76%
673.64
STX
+4.72%
1,614.41
MPWR
+5.74%
343.47
TER
+12.12%

FAQ

What Is the Insmed (INSM) Stock Price Today?

The Insmed stock price today is 136.33 USD.

What Stock Exchange Does Insmed Trade On?

Insmed is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Insmed?

The stock symbol for Insmed is "INSM."

What Is the Insmed Market Cap?

As of today, Insmed market cap is 29.43B USD.

What Is Insmed's Earnings Per Share (TTM)?

The Insmed EPS (TTM) is -6.42.

When Is the Next Insmed Earnings Date?

Insmed will release its next earnings report on May 07, 2026.

From a Technical Analysis Perspective, Is INSM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Insmed Stock Split?

Insmed has split 2 times.

What is the current trading status of Insmed (INSM)?

As of May 01, 2026, Insmed (INSM) is trading at a price of 136.33 USD, with a previous close of 136.33 USD. The stock has fluctuated within a day range of 134.94 USD to 137.22 USD, while its 52-week range spans from 63.81 USD to 212.75 USD.

What Is Insmed (INSM) Price Target According to Analysts?

The average 12-month price target for Insmed is 212.70 USD, with a high estimate of 243 USD and a low estimate of 177 USD. 21 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +56.02% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.